News & Updates
Filter by Specialty:
Kidney, heart benefits FLOW with semaglutide
Semaglutide reduces the risk of major kidney disease-related events and death from cardiovascular causes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the FLOW* study presented at ERA 2024.
Kidney, heart benefits FLOW with semaglutide
10 Jul 2024
TMI, fludarabine, melphalan pass phase I trial as conditioning therapy in multiple myeloma
Fludarabine, melphalan, and total marrow irradiation (TMI) 900 cGy may be utilized as conditioning for allogeneic stem cell transplantation in patients with high-risk or relapsed/refractory multiple myeloma, as shown in a phase I trial.
TMI, fludarabine, melphalan pass phase I trial as conditioning therapy in multiple myeloma
10 Jul 2024
Nomogram predicts acute radiation enteritis in cervical cancer
A nomogram model displays a decent performance in predicting grade ≥2 acute radiation enteritis (ARE) among patients with cervical cancer receiving concurrent chemoradiotherapy, a study has shown.
Nomogram predicts acute radiation enteritis in cervical cancer
10 Jul 2024
Bulky tumours in PCNSL tied to high local treatment failure
Systemic and intrathecal therapies are necessary for local control in patients with primary central nervous system lymphoma (PCNSL), but bulky tumours remain a problem, according to a study.
Bulky tumours in PCNSL tied to high local treatment failure
10 Jul 2024
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.
